Pharvaris N.V.
The article says a third-party “Claude Portfolio” account added positions in Pharvaris (PHVS) and Micron Technology (MU). For PHVS, it cites a prevention trial with results due before Sept. 30 and models about 80% success odds versus ~50% priced in, with a downside to around $16. For MU, it cites tight 2027 DRAM/HBM supply and a modeled ~14% upside.
Analysts issued multiple Wall Street calls, including UBS initiating Crescent Energy (CRGY) with Buy and $13 target, and UBS initiating SM Energy (SM) with Buy and $36 target. Raymond James reiterated Nvidia (NVDA) as strong buy. UBS reiterated SpaceX as buy, citing a July 16 Starship test flight. Deutsche Bank reiterated Tesla (TSLA) ahead of earnings. Citi lowered Microsoft (MSFT) target to $570 from $620.
Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
Over the past 7 days, alphai's AI scored 1 news story mentioning PHVS (Pharvaris N.V.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PHVS coverage spans insider activity, financial news and regulation.
In the last 30 days, PHVS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($80K). The most active reporter was Modig Berndt, Chief Executive Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term catalyst framing around the prevention trial could drive speculative positioning and volatility into the Sep 30 window.
Biotech initiation with a quantified PT can meaningfully affect risk appetite for the name.
Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
This is an insider sale disclosure; it may slightly affect sentiment but does not change fundamentals by itself.
Routine 10b5-1 insider sale; typically limited signal value, but can slightly affect near-term sentiment if investors treat it as a read-through.
alphai scores every news story that mentions PHVS with an AI model for sentiment and relevance, and aggregates insider trades from Pharvaris N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article says a third-party “Claude Portfolio” account added positions in Pharvaris (PHVS) and Micron Technology (MU). For PHVS, it cites a prevention trial with results due before Sept. 30 and models about 80% success odds versus ~50% priced in, with a downside to around $16. For MU, it cites tight 2027 DRAM/HBM supply and a modeled ~14% upside.
5 min readAnalysts issued multiple Wall Street calls, including UBS initiating Crescent Energy (CRGY) with Buy and $13 target, and UBS initiating SM Energy (SM) with Buy and $36 target. Raymond James reiterated Nvidia (NVDA) as strong buy. UBS reiterated SpaceX as buy, citing a July 16 Starship test flight. Deutsche Bank reiterated Tesla (TSLA) ahead of earnings. Citi lowered Microsoft (MSFT) target to $570 from $620.
7 min readPharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
4 min readSchikan Johannes Gerardus Christiaan Petrus sold 37,600 shares of Pharvaris N.V. (PHVS) at an average of $35.41 ($35.05–$35.49, $1.33M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLesage Anne (Chief Early Development) sold 37,700 indirectly-held shares of Pharvaris N.V. (PHVS) at an average of $35.41 ($35.05–$35.49, $1.33M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLesage Anne (Chief Early Development) sold 38,472 shares of Pharvaris N.V. (PHVS) at an average of $35.37 ($35.05–$35.48, $1.36M total) across 3 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLu Peng (Chief Medical Officer) sold 29,700 shares of Pharvaris N.V. (PHVS) at an average of $34.30 ($34.00–$35.09, $1.02M total) across 3 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.
2 min readMonges Viviane sold 9,667 shares of Pharvaris N.V. (PHVS) at $30.29 ($0.29M total) on 2026-05-21.
2 min readNijdam Anna (Principal Accounting Officer) sold 1,829 shares of Pharvaris N.V. (PHVS) at $30.60 on 2026-05-21.
1 min readNassif David W. (CFO / CLO) sold 10,000 shares of Pharvaris N.V. (PHVS) at $30.31 ($0.30M total) on 2026-05-21.
1 min read
